ClinicalTrials.gg
CompletedNCT07255040Updated Aug 5, 2026

A Clinical Study to Evaluate the Effectiveness of an Experimental Toothpaste in Improving Gum Health and Reducing Plaque Accumulation

An interventional study of Test Dentifrice and Parodontax Complete Protection in Dental Plaque and Gingivitis, sponsored by HALEON. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by HALEON · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
284
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies in Dental Plaque with a site in United States — 7 open to participants now, 8 under way, 1 of them phase 3. Dental Plaque · United States.

Enrollment
3rd of 59
284 · median 80
Started
2025
with 3 others
No phase
33 of 65
6 open now
Registered
56th of 65
by date
Lead sponsor
4 of 65
HALEON

Among the 65 studies in Dental Plaque with a site in United States, this one is the 3rd largest by enrollment of the 59 interventional ones that give a count, is one of 4 that started in 2025, is one of 33 with no phase, and was the 56th registered.

Dental Plaque

352 studies on the registry are indexed under Dental Plaque; 60 are open to participants now.

Browse Dental Plaque studies →

Open to participants now

7 of the 65 studies in Dental Plaque with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Dental Plaque studies recruiting now, 10 (29%) set no upper age limit and 20 (57%) stop at 75 or younger; 14 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Dental Plaque with a site in United States, or all of them as a file.
02

Study summary

The aim of this 24-week clinical study is to evaluate the ability of an experimental dentifrice containing 0.454 percent (%) weight by weight (w/w) Stannous fluoride (SnF2); to improve gingival health, plaque reduction and prevention of plaque accumulation compared with a regular fluoride dentifrice (negative control) in participants with mild to moderate gingivitis.

Read the detailed description

This will be a single-center, 24-week, randomized, controlled, single blind (examiner only), 3-treatment arms, parallel group, stratified study, to evaluate the efficacy of using an experimental dentifrice containing 0.454% w/w Stannous fluoride, twice daily in reducing gingivitis and plaque accumulation in a population with clinically measurable level of gingivitis. The clinical efficacy of the experimental dentifrice will be compared to a commercially available regular fluoride dentifrice as negative control. In addition, a marketed dentifrice containing 0.454% w/w SnF2 is included as positive control to provide a well-established benchmark. Approximately 300 participants (approximately 100 per group) will be randomized to ensure approximately 270 evaluable participants (approximately 90 per group) complete the study.

03

Conditions studied

  • Dental Plaque
  • Gingivitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant provision of a signed and dated document indicating that the participant has been informed of all pertinent aspects of the study before any assessment is performed.
  • Participant is of either sex and any gender who, at the time of screening, is at least 18 years old, inclusive.
  • A participant who is willing and able to comply with scheduled visits, treatment plan and other study procedures.
  • A participant in good general and mental health with, in the opinion of the investigator or medically qualified designee, no or relevant abnormalities in medical history or upon oral examination, or condition, that would impact the participant 's safety, wellbeing or the outcome of the study, if they were to participate in the study, or affect the individual's ability to understand and follow study procedures and requirements.

Exclusion criteria

Exclusion Criteria:

  • A participant who is an employee of the site, either directly involved in the conduct of the study or a member of their immediate family; or an employee of the investigational site otherwise supervised by the investigator; or a Haleon employee directly involved in the conduct of the study or a member of their immediate family.
  • A participant who has participated in other studies (including non-medicinal studies) involving investigational product(s) within 30 days prior to study entry and/or during study participation.
  • A participant with, in the opinion of the investigator or medically qualified designee, an acute or chronic medical, psychiatric condition or laboratory abnormality or any other clinical serious or unstable conditions (example, cardiovascular diseases, diabetes, liver disorders, and kidney disorders) that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator or medically qualified designee, would make the participant inappropriate for entry into this study.
  • A female participant who is a pregnant (self-reported) or intending to become pregnant over the duration of the study or who is breastfeeding.
  • A participant with known or suspected intolerance or to the study materials (or closely related compounds) or any of their stated ingredients.
  • A participant unwilling or unable to comply with the Lifestyle Considerations described in this protocol.
  • A participant who is a current smoker or an ex-smoker (including vaping) who stopped within 6 months of Screening or who is using smokeless forms of tobacco (example, chewing tobacco, gutkha, pan containing tobacco, nicotine-based e-cigarettes).
  • A participant who is diagnosed with xerostomia or is taking any medication that in the view of the investigator is causing xerostomia.
  • A participant who has a medical condition which could have directly influenced gingival bleeding (example, type 2 diabetes) or who has a bleeding disorder that could have affected study outcomes and/or participant safety.
  • A participant who has a recent history (within the last year) of alcohol or other substance abuse.
  • A participant who has a severe oral condition (example, acute necrotizing ulcerative gingivitis or oral or peri-oral ulceration including herpetic lesions) that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant/examiner if they participate in the study.
  • Presence of a tongue or lip piercing, or any other oral feature that could interfere with the usage of a toothbrush.
  • Dental Exclusions:

    1. A participant who has active caries that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant if they participate in the study.
    2. A participant who has dentures (partial or full).
    3. A participant who has fixed orthodontic appliances or is undergoing active or recent (within 3 months of Screening) orthodontic treatment, which in the opinion of the investigator, could interfere with study procedures, assessments or outcomes.
    4. A participant who has other orthodontic devices (example, bands, fixed retainers, or removable retainers) that could, in the opinion of the investigator, interfere with study procedures, assessment or outcomes.
    5. A participant who has numerous restorations in a poor state of repair.
    6. A participant who has any dental condition (example, overcrowding) that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant if they participate in the study.
    7. A participant who has had dental prophylaxis within 12 weeks of Screening.
    8. A participant who has had teeth bleaching within 12 weeks of Screening.
    9. A participant who has high levels of extrinsic stain or calculus deposits, in the opinion of the investigator, that could have interfered with plaque assessments.
  • A participant who has previously been enrolled in this study.
  • A participant who, in the opinion of the investigator or medically qualified designee, should not participate in the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
284 participants (actual)

Study arms

  • Experimental
    Test Dentifrice

    Participants will be instructed to brush their teeth thoroughly with Test Dentifrice for at least one (timed) minute twice a day (morning and evening) for 24 weeks.

    Drug: Test Dentifrice

  • Active comparator
    Reference Dentifrice (Positive Control)

    Participants will be instructed to brush their teeth thoroughly with Reference Dentifrice (Positive Control) for at least one (timed) minute twice a day (morning and evening) for 24 weeks.

    Drug: Parodontax Complete Protection

  • Active comparator
    Reference Dentifrice (Negative Control)

    Participants will be instructed to brush their teeth thoroughly with Reference Dentifrice (Negative Control) for at least one (timed) minute twice a day (morning and evening) for 24 weeks.

    Drug: Colgate Cavity Protection

Interventions

  • DrugTest Dentifrice

    Experimental dentifrice containing 0.454% w/w SnF2.

  • DrugParodontax Complete Protection

    Marketed dentifrice containing 0.454% w/w SnF2.

  • Marketed regular fluoride dentifrice.

06

What researchers measure

Primary outcomes

  1. Number of Bleeding Sites (Overall) at Week 24

    Number of bleeding sites will be assessed using the bleeding index (BI) assessment. BI will be assessed for all evaluable surfaces of the facial and lingual/palatal gingiva, six sites per tooth. The probe will be inserted approximately 1 millimeter (mm) into the gingival sulcus and moved around the tooth from the distal interproximal area to the mesial interproximal area, gently stretching the gingival epithelium. The number of bleeding sites for each participant will be calculated as the number of tooth sites with bleeding observed immediately on probing or within 30 seconds of probing.

    Time frame: Week 24

Secondary outcomes

  1. Number of Bleeding Sites (Overall) at Weeks 1, 4 and 12

    Number of bleeding sites will be assessed using the BI assessment. BI will be assessed for all evaluable surfaces of the facial and lingual/palatal gingiva, six sites per tooth. The probe will be inserted approximately 1 mm into the gingival sulcus and moved around the tooth from the distal interproximal area to the mesial interproximal area, gently stretching the gingival epithelium. The number of bleeding sites for each participant will be calculated as the number of tooth sites with bleeding observed immediately on probing or within 30 seconds of probing.

    Time frame: Weeks 1, 4 and 12

  2. Number of Bleeding Sites (Interproximal) at Weeks 1, 4 and 12

    Number of bleeding sites will be assessed using the BI assessment. BI will be assessed for all evaluable surfaces of the facial and lingual/palatal gingiva, six sites per tooth. The probe will be inserted approximately 1 mm into the gingival sulcus and moved around the tooth from the distal interproximal area to the mesial interproximal area, gently stretching the gingival epithelium. The number of bleeding sites for each participant will be calculated as the number of tooth sites with bleeding observed immediately on probing or within 30 seconds of probing.

    Time frame: Weeks 1, 4 and 12

  3. Number of Bleeding Sites (Interproximal) at Week 24

    Number of bleeding sites will be assessed using the BI assessment. BI will be assessed for all evaluable surfaces of the facial and lingual/palatal gingiva, six sites per tooth. The probe will be inserted approximately 1 mm into the gingival sulcus and moved around the tooth from the distal interproximal area to the mesial interproximal area, gently stretching the gingival epithelium. The number of bleeding sites for each participant will be calculated as the number of tooth sites with bleeding observed immediately on probing or within 30 seconds of probing.

    Time frame: Week 24

  4. Mean BI (Overall) at Weeks 1, 4, 12 and 24

    The BI is an invasive assessment of gingival bleeding. BI will be assessed for all evaluable surfaces of the facial and lingual/palatal gingiva, six sites per tooth. The probe will be inserted approximately 1 mm into the gingival sulcus and moved around the tooth from the distal interproximal area to the mesial interproximal area, gently stretching the gingival epithelium. Gingival bleeding will be scored on a 3-points scale with scores ranging from 0 to 2, where 0=Absence of bleeding on probing, 1=Bleeding observed within 30 seconds of probing, 2=Bleeding observed immediately on probing. Mean BI will be calculated by taking the average over all tooth sites assessed for a participant. Lower score indicates improvement in the symptoms.

    Time frame: Weeks 1, 4, 12 and 24

  5. Mean BI (Interproximal) at Weeks 1, 4, 12 and 24

    The BI is an invasive assessment of gingival bleeding. BI will be assessed for all evaluable surfaces of the facial and lingual/palatal gingiva, six sites per tooth. The probe will be inserted approximately 1 mm into the gingival sulcus and moved around the tooth from the distal interproximal area to the mesial interproximal area, gently stretching the gingival epithelium. Gingival bleeding will be scored on a 3-points scale with scores ranging from 0 to 2, where 0=Absence of bleeding on probing, 1=Bleeding observed within 30 seconds of probing, 2=Bleeding observed immediately on probing. Mean BI will be calculated by taking the average over all tooth sites assessed for a participant. Lower score indicates improvement in the symptoms.

    Time frame: Weeks 1, 4, 12 and 24

  6. Mean Modified Gingival Index (MGI) (Overall) at Weeks 1, 4, 12 and 24

    The MGI assessment is a non-invasive evaluation which focuses on the visual symptoms of gingivitis (for example, redness, texture, edema). The MGI will be assessed on the buccal and lingual marginal gingiva and interdental papillae of all scorable teeth. Three scores will be recorded buccally/labially and three scores lingually/palatally using a 5-point scale ranging from 0 to 4, where 0 = Absence of inflammation, 1= Mild inflammation: slight change in color, little change in texture of any portion of the marginal or papillary gingival unit, 2=Mild inflammation: criteria as \[1\] but involving the entire marginal or papillary gingival unit, 3=Moderate inflammation: glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit, 4=Severe inflammation: marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicates improvement in the symptoms.

    Time frame: Weeks 1, 4, 12 and 24

  7. Mean MGI (Interproximal) at Weeks 1, 4, 12 and 24

    The MGI assessment is a non-invasive evaluation which focuses on the visual symptoms of gingivitis (for example, redness, texture, edema). The MGI will be assessed on the buccal and lingual marginal gingiva and interdental papillae of all scorable teeth. Three scores will be recorded buccally/labially and three scores lingually/palatally using a 5-point scale ranging from 0 to 4, where 0 = Absence of inflammation, 1= Mild inflammation: slight change in color, little change in texture of any portion of the marginal or papillary gingival unit, 2=Mild inflammation: criteria as \[1\] but involving the entire marginal or papillary gingival unit, 3=Moderate inflammation: glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit, 4=Severe inflammation: marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicates improvement in the symptoms.

    Time frame: Weeks 1, 4, 12 and 24

  8. Mean Turesky Plaque Index (TPI) (Overall) at Weeks 1, 4, 12 and 24

    TPI will be used to assess plaque on all gradable teeth. The plaque will first be disclosed using a plaque disclosing dye solution. The TPI will be assessed on the facial and lingual surfaces of each scorable tooth. Three scores will be recorded buccally/labially and three scores lingually/palatally. Disclosed plaque will be scored on a scale ranging from 0-6, where 0=No plaque, 1=Separate flecks of plaque at the cervical margin, 2=Thin continuous band of plaque (up to 1 mm) at the cervical margin, 3=Band of plaque wider than 1 mm but covering less than (\<)1/3 of the tooth surface, 4=Plaque covering greater than or equal to (\>=)1/3 but \<2/3 of the tooth surface, 5=Plaque covering \>=2/3 of the tooth surface. Lower score indicates improvement in the symptoms.

    Time frame: Weeks 1, 4, 12 and 24

  9. Mean TPI (Interproximal) at Weeks 1, 4, 12 and 24

    TPI will be used to assess plaque on all gradable teeth. The plaque will first be disclosed using a plaque disclosing dye solution. The TPI will be assessed on the facial and lingual surfaces of each scorable tooth. Three scores will be recorded buccally/labially and three scores lingually/palatally. Disclosed plaque will be scored on a scale ranging from 0-6, where 0=No plaque, 1=Separate flecks of plaque at the cervical margin, 2=Thin continuous band of plaque (up to 1 mm) at the cervical margin, 3=Band of plaque wider than 1 mm but covering \<1/3 of the tooth surface, 4=Plaque covering \>=1/3 but \<2/3 of the tooth surface, 5=Plaque covering \>=2/3 of the tooth surface. Lower score indicates improvement in the symptoms.

    Time frame: Weeks 1, 4, 12 and 24

  10. Change in Mean TPI From Pre to Post Single Brush at Baseline

    TPI will be used to assess plaque on all gradable teeth. The plaque will first be disclosed using a plaque disclosing dye solution. The TPI will be assessed on the facial and lingual surfaces of each scorable tooth. Three scores will be recorded buccally/labially and three scores lingually/palatally. Disclosed plaque will be scored on a scale ranging from 0-6, where 0=No plaque, 1=Separate flecks of plaque at the cervical margin, 2=Thin continuous band of plaque (up to 1 mm) at the cervical margin, 3=Band of plaque wider than 1 mm but covering \<1/3 of the tooth surface, 4=Plaque covering \>=1/3 but \<2/3 of the tooth surface, 5=Plaque covering \>=2/3 of the tooth surface. Lower score indicates improvement in the symptoms. Change in TPI will be calculated by subtracting pre brushing TPI score from post brushing TPI score at Baseline.

    Time frame: Pre to Post Brushing at Baseline

07

Study locations

1 site
  • Salus Research, Inc.
    Fort Wayne, Indiana 46825, United States
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trial-register@haleon.com

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2025 to primary completion in Jul 2026, 8 months.

Of 45 industry-sponsored interventional studies with no phase under Dental Plaque, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 8 months is above that.

Counting every sponsor, half of 178 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Nov 28, 2025
StartActual
Nov 19, 2025
Primary completionActual
Jul 30, 2026
CompletionActual
Jul 30, 2026
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07255040
Lead sponsor
HALEON
Responsible party
Sponsor
First posted
Nov 28, 2025
Start date
Nov 19, 2025
Primary completion
Jul 30, 2026
Completion
Jul 30, 2026
Last update
Aug 5, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion